ライフサイエンスコーパス: macular edema

1 provement of best-corrected visual acuity or macular edema.

2 age-related macular degeneration or diabetic macular edema.

3 VO and HRVO patients receiving treatment for macular edema.

4 r leakage observed in patients with diabetic macular edema.

5 l coherence tomography detection of diabetic macular edema.

6 eration, vitreomacular traction, and cystoid macular edema.

7 retinopathy (DR) in the absence of diabetic macular edema.

8 age-related macular degeneration or diabetic macular edema.

9 increased vascular permeability in diabetic macular edema.

10 ly lower in the DRL of subjects with uveitic macular edema.

11 measured by the incidence of POE and cystoid macular edema.

12 age-related macular degeneration or diabetic macular edema.

13 reated with Dexamethasone implant 0.7 mg for macular edema.

14 eration, retinal vein occlusion and diabetic macular edema.

15 of spreading capillary loss with associated macular edema.

16 macotherapy for treatment of CRVO-associated macular edema.

17 er factors is an important cause of diabetic macular edema.

18 to treatment in severely affected eyes with macular edema.

19 illary nonperfusion in eyes without diabetic macular edema.

20 71 (38) microm in the 7 exposed eyes without macular edema.

21 e largest increases at the time of recurrent macular edema.

22 ce of proliferative diabetic retinopathy and macular edema.

23 ce of proliferative diabetic retinopathy and macular edema.

24 graphs gradable for diabetic retinopathy and macular edema.

25 growth factor for the treatment of diabetic macular edema.

26 betic retinopathy in the absence of diabetic macular edema.

27 erity scale score or development of diabetic macular edema.

28 ss in RP patients with no history of cystoid macular edema.

29 ior segment, especially in eyes with uveitic macular edema.

30 f the 61 eyes (29.5%) also developed cystoid macular edema.

31 early treatment-naive clinically significant macular edema.

32 epiretinal membrane (0.16/EY), and recurrent macular edema (0.09/EY).

33 and serum samples of patients with diabetic macular edema (1.6-fold) measured by Western blot and EL

34 Postoperative complications included cystoid macular edema (10%), corneal decompensation (6%), and ch

35 50.9%), posterior synechiae (21.7%), cystoid macular edema (16%), epiretinal membrane (13.2%), glauco

36 ferative diabetic retinopathy (NPDR) without macular edema, 20 eyes had proliferative diabetic retino

37 tension (29 eyes, 10%) and transient cystoid macular edema (25 eyes, 8.6%).

38 309 (78) microm in the 6 eyes with diagnosed macular edema, 279 (23) microm in the fellow eyes, and 2

39 face changes, or both (24 eyes); sequelae of macular edema (3 eyes); blunt trauma (2 eyes); retinal p

40 ications occurred in 5.2%, primarily cystoid macular edema (3.7%).

41 f 124 eyes analyzed, 60 (48.4%) had diabetic macular edema, 32 (25.8%) had neovascular age-related ma

42 rticipants; 95% CI, 36.6%-39.4%) followed by macular edema (7% of participants; 95% CI, 6.3%-7.7%).

43 The major complications included macular edema (91%), cataract (93%), glaucoma (35%), and

44 retinal vascular permeability contributes to macular edema, a leading cause of vision loss in eye pat

45 subretinal fluid, subretinal hemorrhage, or macular edema after 4 anti-VEGF injections and anti-VEGF

46 Treatment-naive eyes with macular edema after BRVO were included in the study if t

47 han grid laser photocoagulation in eyes with macular edema after BRVO.

48 Cystoid macular edema after cataract surgery has a tendency to r

49 ased RR (RR, 1.80; 95% CI, 1.36-2.36) of new macular edema after surgery.

50 es, new vessels, fibrous proliferations, and macular edema, agreement was substantial (weighted kappa

51 atment-naive patients with radiation-induced macular edema and a resulting decrease in visual acuity

52 Approximately one third of diabetic macular edema and age-related macular degeneration clini

53 mized trial data on 660 adults with diabetic macular edema and decreased VA (Snellen equivalent, appr

54 r until macular edema resolved or until both macular edema and HEs resolved.

55 steroids, and procedures primarily targeting macular edema and neovascularization.

56 participants) with center-involved diabetic macular edema and no preexisting open-angle glaucoma, 26

57 In eyes with center-involved diabetic macular edema and no prior open-angle glaucoma, repeated

58 In addition to vision loss caused by macular edema and pathological angiogenesis, DR patients

59 patients with radiation retinopathy-related macular edema and prevent vision loss through 48 weeks o

60 tion significantly declined for treatment of macular edema and proliferative retinopathy.

61 sociated with presenting vision in eyes with macular edema and RVO, most eyes treated with ranibizuma

62 ing the search terms diabetic retinopathy OR macular edema AND stroke OR cerebrovascular disease OR c

63 having diabetic retinopathy without diabetic macular edema and underwent fluorescein angiography and

64 jections every 8 weeks maintained control of macular edema and visual benefits through week 52.

65 ibercept Injection in Patients With Diabetic Macular Edema) and VIVID (Intravitreal Aflibercept Injec

66 ibercept Injection in Patients With Diabetic Macular Edema) and VIVID (Intravitreal Aflibercept Injec

67 iferative diabetic retinopathy (PDR) without macular edema, and 27 eyes had diabetic macular edema (D

68 previously combined, expands the section on macular edema, and adds several characteristics not prev

69 ties, such as angle closure glaucoma, cystic macular edema, and exudative retinal detachment.

70 o 7 times for diabetic retinopathy, diabetic macular edema, and image gradability by a panel of 54 US

71 change, proportion of patients with resolved macular edema, and leakage on fluorescein angiography.

72 y (BCVA) change from baseline, resolution of macular edema, and number of adjunctive treatments.

73 r age-related macular degeneration, diabetic macular edema, and retinal venous occlusive disease.

74 nge-like diffuse retinal thickening, cystoid macular edema, and serous retinal detachment.

75 Eyes with early subclinical macular edema are at significantly higher risk for futur

76 ative diabetic retinopathy, and incidence of macular edema as assessed via grading of color stereo fi

77 f nonproliferative DR, proliferative DR, and macular edema, as well as stereoscopic fundus photograph

78 reatment of decreased vision attributable to macular edema associated with central retinal vein occlu

79 treal aflibercept (IVA) for the treatment of macular edema associated with CRVO based on data from th

80 degradable implant approved for treatment of macular edema associated with retinal vein occlusion (RV

81 lateral synechiae, bilateral papilledema and macular edema associated with serous retinal detachment

82 Eyes with subclinical macular edema at baseline (and at 4 months after plaque

83 50%) compared with eyes without subclinical macular edema at baseline (n = 39; 30%) (P = 0.005; haza

84 FAi-treated eyes had investigator-determined macular edema at month 36 compared with sham-treated eye

85 -VEGF treatment, but longer mean duration of macular edema before randomization (18 months vs. 1 mont

86 rative retinopathy or clinically significant macular edema, both of which require timely intervention

87 ti-VEGF therapy for center-involved diabetic macular edema (CI-DME) in a 2-year randomized clinical t

88 Center-involved diabetic macular edema (ci-DME) is a major cause of vision loss.

89 Patients with center-involved diabetic macular edema (CI-DME) with good visual acuity (VA) repr

90 Cystoid macular edema (CME) before intraocular surgery was not e

91 kness (2.9 mm vs. 3.2 mm; P = 0.01), cystoid macular edema (CME) involving the foveola (30% vs. 70%;

92 Cystoid macular edema (CME) is a leading cause of blindness.

93 a vitreous haze score of >/=1.5+ or cystoid macular edema (CME) of >300 mum were enrolled.

94 y (VA), complications, resolution of cystoid macular edema (CME), and anterior chamber and vitreous i

95 best corrected visual acuity (BCVA), cystoid macular edema (CME), and the highest fluorescein angiogr

96 tion, epiretinal membrane (ERM), and cystoid macular edema (CME), were analyzed.

97 ual acuity (VA) in eyes with uveitic cystoid macular edema (CME).

98 ar pressure (IOP) increase (n = 12), cystoid macular edema (CME; n = 3), and nonarteritic anterior is

99 al hemorrhage, infectious keratitis, cystoid macular edema [CME], retinal detachment [RD], or RD surg

100 ETDRS] of 55 letters or better); (2) cystoid macular edema (CMO), foveal thickness, and macular volum

101 o macular ischemia, and has a higher risk of macular edema compared to eyes with no vasculitis.

102 Retinal vasculitis had twice the risk of macular edema compared to the non-vasculitis group.

103 oliferative DR (PDR), clinically significant macular edema (CSME), diabetic macular edema (DME), or o

104 nce of DME, including clinically significant macular edema (CSME), on monocular fundus photographs us

105 proliferative DR, or clinically significant macular edema (CSME).

106 for the detection of clinically significant macular edema (CSME).

107 oliferative DR [PDR], clinically significant macular edema [CSME], or both who had evidence of retina

108 Patients with neovascular AMD and persistent macular edema despite fixed-interval intravitreous anti-

109 d hyperemia and swelling of the optic nerve, macular edema, diffuse intraretinal hemorrhages, and dil

110 tinopathy (n = 9) and patients with diabetic macular edema (DME) (n = 31) were compared with healthy

111 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy

112 The prevalence of persistent diabetic macular edema (DME) after months of anti-vascular endoth

113 tive diabetic retinopathy (PDR), or diabetic macular edema (DME) and procedure codes for retinopathy

114 Patients with diabetic macular edema (DME) are at high risk of vascular complic

115 d characterization of patients with diabetic macular edema (DME) are important for individualizing tr

116 (VA 20/32 or worse) center-involved diabetic macular edema (DME) at baseline were required to receive

117 a shorter duration of diabetes and diabetic macular edema (DME) at baseline, were less likely to hav

118 Diabetic macular edema (DME) can be treated with different altern

119 l aflibercept injections (IAIs) for diabetic macular edema (DME) during the phase III VISTA DME trial

120 anretinal photocoagulation rates in diabetic macular edema (DME) eyes did not significantly differ fr

121 n naive and previously treated (PT) diabetic macular edema (DME) eyes in a real-life setting.

122 owth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopat

123 Diagnosing diabetic macular edema (DME) from monocular fundus photography vs

124 ased macular thickness in eyes with diabetic macular edema (DME) in clinical trials.

125 r agents are effective for treating diabetic macular edema (DME) involving the center of the macula (

126 nibizumab (0.3 mg) for treatment of diabetic macular edema (DME) involving the center of the retina a

127 Diabetic macular edema (DME) is a leading cause of vision loss in

128 For example, diabetic macular edema (DME) is a leading cause of vision loss in

129 al dexamethasone implant therapy in diabetic macular edema (DME) is associated with long-term outcome

130 Diabetic macular edema (DME) is the major cause of vision loss in

131 Diabetic macular edema (DME) is the most common cause of vision l

132 t, bevacizumab, and ranibizumab for diabetic macular edema (DME) might influence interpretation of st

133 potential effect of treatments for diabetic macular edema (DME) on driving should be of value to pat

134 e <75 years, absence of preexisting diabetic macular edema (DME) or postvitrectomy persistent cystoid

135 related macular degeneration (AMD), diabetic macular edema (DME) or retinal vein occlusion (RVO), rec

136 pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection

137 ic fundus photographs, we evaluated diabetic macular edema (DME) progression and DR progression.

138 Patients with diabetic macular edema (DME) received three intravitreal injectio

139 Diabetic macular edema (DME) remains a leading cause of vision lo

140 erity score (DRSS) in patients with diabetic macular edema (DME) treated with intravitreal ranibizuma

141 VEGF) medicines have revolutionized diabetic macular edema (DME) treatment.

142 s and non-perfusion areas (NPAs) in diabetic macular edema (DME) using two different Optical Coherenc

143 Patients with diabetic macular edema (DME) who received sham control or FAc 0.2

144 hout macular edema, and 27 eyes had diabetic macular edema (DME) with either NPDR or PDR.

145 tional characteristics in eyes with diabetic macular edema (DME) with subfoveal neuroretinal detachme

146 growth factor therapy in eyes with diabetic macular edema (DME) with vision loss after macular laser

147 growth factor therapy in eyes with diabetic macular edema (DME) with vision loss after macular laser

148 erative DR (NPDR), 51 with NPDR and diabetic macular edema (DME), and 18 with proliferative DR (PDR)-

149 Retinal hypoxia also contributes to diabetic macular edema (DME), and because of the absence of good

150 related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) we

151 retinopathy (NPDR), with or without diabetic macular edema (DME), and temporarily lost to follow-up.

152 y significant macular edema (CSME), diabetic macular edema (DME), or ocular surgery.

153 herapeutic target for patients with diabetic macular edema (DME), perhaps in combination with current

154 elated macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal n

155 The majority of patients with diabetic macular edema (DME), the most common cause of vision los

156 f varying severity, with or without diabetic macular edema (DME), using en face Doppler OCT.

157 Diabetic retinopathy, diabetic macular edema (DME), vision-threatening diabetic retinop

158 ith or without concomitant baseline diabetic macular edema (DME).

159 e study of diabetic retinopathy and diabetic macular edema (DME).

160 iabetic retinopathy (DR), including diabetic macular edema (DME).

161 otocoagulation for center-involving diabetic macular edema (DME).

162 ercept monotherapy for treatment of diabetic macular edema (DME).

163 hy (OCTA) and treatment response in diabetic macular edema (DME).

164 peripheral vision loss or worsening diabetic macular edema (DME).

165 tivity of AKB-9778 in patients with diabetic macular edema (DME).

166 d meta-analysis of dyslipidemia and diabetic macular edema (DME).

167 ept, ranibizumab and bevacizumab in diabetic macular edema (DME).

168 lated macular degeneration (AMD) or diabetic macular edema (DME).

169 , with ranibizumab in patients with diabetic macular edema (DME).

170 ndard of care for the management of diabetic macular edema (DME).

171 ude different severities of DR, and diabetic macular edema (DME).

172 f 456 patients with center-involved diabetic macular edema (DME).

173 acular degeneration (AMD, n = 400), diabetic macular edema (DME, n = 400), or retinal vein occlusion

174 2 diabetes and severe stages of DR (diabetic macular edema [DME] and proliferative diabetic retinopat

175 r visual-threatening complications (diabetic macular edema [DME] and proliferative diabetic retinopat

176 [NPDR], proliferative DR [PDR], or diabetic macular edema [DME]) or "any DR" (further subclassified

177 on (RVO), diabetic retinopathy (DR; diabetic macular edema, DME), or noninfectious uveitis (NIU).

178 age-related macular degeneration or diabetic macular edema does not respond to an initial anti-vascul

179 age-related macular degeneration or diabetic macular edema does not respond to an initial anti-vascul

180 nited States, and included 362 patients with macular edema due to central retinal or hemiretinal vein

181 Among patients with macular edema due to central retinal or hemiretinal vein

182 d safety of aflibercept for the treatment of macular edema due to central retinal vein occlusion.

183 eal injections are a mandatory treatment for macular edema due to nAMD, DME and RVO.

184 injectable suspension (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO).

185 th Intravitreal Aflibercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE)

186 s not alter choroidal thickness in eyes with macular edema due to RVO, but may result in expansion of

187 38 eyes of 38 treatment-naive patients with macular edema due to RVO, enrolled in the prospective Su

188 5 pregnant women who presented with diabetic macular edema during pregnancy in the period from 2011 t

189 e processes, including postoperative cystoid macular edema, epiretinal membrane formation, macular fo

190 ) is effective for the treatment of diabetic macular edema, even in refractory cases that have failed

191 uring the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) A and B Phase III clinical trials.

192 emorrhage, retinal detachment, retinal tear, macular edema, glaucoma, or choroidal detachment-and use

193 nterval {CI}, 2.15-4.35], P < .001), cystoid macular edema (HR = 2.87 [95% CI, 1.41-5.82], P = .004),

194 % CI, 0.99-3.17], P = .06), the incidence of macular edema (HR, 1.04 [95% CI, 0.83-1.29], P = .74; OR

195 By 2-years' follow-up, macular edema improved in 71% of eyes and resolved in 60

196 429 episodes of recurrent macular edema in 80 eyes were examined.

197 age-related macular degeneration or diabetic macular edema in a 9-member retinal specialty private pr

198 ctious and nontumoral uveitis complicated by macular edema in at least 1 eye.

199 ly on central subfield thickness to quantify macular edema in central and branch retinal vein occlusi

200 In the treatment of macular edema in CRVO, IVB yields the best cost utility

201 A cut-off CFT value for treatment of macular edema in IU, in the presence of other relevant m

202 gnosis of cystoid macular edema or new-onset macular edema in patients with diabetes, recorded by a h

203 abetic retinopathy or clinically significant macular edema in patients with various initial retinopat

204 tection of diabetic retinopathy and diabetic macular edema in retinal fundus photographs.

205 ying pathophysiologic foundation for cystoid macular edema in retinal vascular diseases.

206 Cystoid macular edema in retinal vein occlusion occurred in rela

207 e early detection and treatment of recurrent macular edema in retinal vein occlusion.

208 te key clinical observations of ischemia and macular edema in the posterior pole and ischemia in the

209 Four eyes (12%) had cystoid macular edema in the repositioning group compared with 5

210 wn to prevent the recurrence or worsening of macular edema in uveitic patients with a history of CME

211 Diabetic macular edema involving the foveal center that presented

212 Diabetic macular edema involving the foveal center was observed b

213 ults (mean age, 61+/-10 years) with diabetic macular edema involving the macular center to receive in

214 Diabetic macular edema is a major complication of diabetes result

215 Pseudophakic cystoid macular edema is common after phacoemulsification catara

216 Diabetic macular edema is one of the leading causes of vision los

217 Macular edema is the leading cause of vision loss in bil

218 litis and low-grade vitritis with or without macular edema may have birdshot chorioretinopathy eviden

219 vitreoretinal traction (57.1%), and chronic macular edema (ME) (71.4%).

220 fficacy variables were: patients (%) in whom macular edema (ME) developed (>/=30% increase from preop

221 Macular edema (ME) is the leading cause of decreased vis

222 (CST), and ellipsoid zone (EZ) integrity in macular edema (ME) patients.

223 vacizumab to ranibizumab in the treatment of macular edema (ME) resulting from retinal vein occlusion

224 erapeutic alternatives for the management of macular edema (ME) secondary to branch retinal vein occl

225 cteristic retinal vascular lesions including macular edema (ME), a leading cause of vision loss in DR

226 retinal vein occlusion (BRVO) complicated by macular edema (ME).

227 d frequent topical steroids for postsurgical macular edema (ME).

228 nal vein occlusion disease (BRVO) cases with macular edema (ME).

229 ts with noninfectious uveitis complicated by macular edema (ME).

230 luid in the retina [i.e., the development of macular edema, (ME)].

231 phthalmoscopic examination features included macular edema, mild intraretinal pigment migration, and

232 53 and/or presence of clinically significant macular edema; n = 95) using the modified Airlie House c

233 on and intravitreal therapy to treat cystoid macular edema not originating from the optic disc.

234 e not associated with clinically significant macular edema (NPA, P = 0.99; NPI, P = 0.67), nor correl

235 Cystoid macular edema observed on SD OCT in very preterm infants

236 Pseudophakic macular edema occurs commonly after phacoemulsification

237 A (88.9% vs 62.5%, P = .05), and presence of macular edema on OCT (33.3% vs 6.2%, P = .04).

238 Diagnosis of cystoid macular edema or new-onset macular edema in patients wit

239 iss Meditec, Dublin, CA) OCTA images with no macular edema or significant motion artifact were acquir

240 rs in the macula following PRP, unrelated to macular edema or thickening, in line with the mathematic

241 mmonly associated with postoperative cystoid macular edema (OR = 0.36, 95% CI: 0.14-0.91, P = 0.031)

242 Black race was associated with a risk of macular edema (OR, 2.86; 95% CI, 1.41-5.79).

243 rse diabetic retinopathy, referable diabetic macular edema, or both, were generated based on the refe

244 patients with different subtypes of diabetic macular edema over a 6-month follow-up period.

245 reatment of decreased vision attributable to macular edema owing to CRVO or HRVO.

246 a (DME) or postvitrectomy persistent cystoid macular edema (P < .05).

247 15), retinal detachments (P = 0.76), cystoid macular edema (P = 0.83), or timing of complications bet

248 Diabetic macular edema patients with VMA have a greater potential

249 n for the prevention of pseudophakic cystoid macular edema (PCME) using a prospective, randomized, do

250 At 28 days postsurgery, pseudophakic cystoid macular edema (PCME) was reported in 8 eyes, of which 7

251 s (NSAIDs) on the incidence of postoperative macular edema (PME) after cataract surgery.

252 e best-corrected visual acuity, incidence of macular edema, posterior capsular opacification, epireti

253 Cystoid macular edema refractory to carbonic anhydrase inhibitor

254 f exudative macular degeneration or diabetic macular edema requiring bilateral anti-vascular endothel

255 avitreal ranibizumab injections either until macular edema resolved or until both macular edema and H

256 rovement can continue in some patients after macular edema resolves and CFT decreases stabilize.

257 % vs. 14.7% and 13.0% vs. 27.3% for BCVA and macular edema, respectively).

258 changes in BCVA from baseline at 2 years by macular edema response status were: resolution, +10 lett

259 nstrated that VEGF is a major contributor to macular edema resulting from retinal vein occlusion, als

260 control, worsening of visual acuity, cystoid macular edema, retroprosthetic membrane formation, persi

261 n foveal development that may be impacted by macular edema, ROP, or both.

262 sual acuity (BCVA) in retinal vein occlusion macular edema (RVO-ME).

263 f DEX implant treatment in 289 patients with macular edema secondary to branch or central RVO (BRVO,

264 ia in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion

265 inferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretina

266 Questionnaire (NEI VFQ-25), in patients with macular edema secondary to central retinal vein occlusio

267 led observational case study of 30 eyes with macular edema secondary to central retinal vein occlusio

268 gain in a broad population of patients with macular edema secondary to CRVO, including those with ma

269 nd safety of DEX implant in the treatment of macular edema secondary to retinal vein occlusion (RVO)

270 Cystoid macular edema seems to be a marker for poorer visual out

271 the macular region, as epiretinal membrane, macular edema, subretinal fluid or alterations of the ou

272 ired blood-retinal barrier function leads to macular edema that is closely associated with the deteri

273 ome an interesting novel target for diabetic macular edema therapy.

274 and mean number of months from diagnosis of macular edema to randomization was 6 (range, 0-104 month

275 The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured

276 Sixteen patients with NPDR without macular edema underwent SDOCT and OCTA.

277 elial growth factor agents to treat diabetic macular edema warrant further assessment.

278 abetic retinopathy or clinically significant macular edema was 1.0% over 5 years among patients with

279 The mean (SD) time to resolution of macular edema was 5.2 (1.3) days; the final central subf

280 Macular edema was defined as a center macular thickness

281 oth central and branch occlusions, recurrent macular edema was detected in non-central macular fields

282 The risk for the development of cystoid macular edema was found to be associated with recurrence

283 Macular edema was less likely to resolve in eyes that re

284 abetic retinopathy or clinically significant macular edema was limited to approximately 5% between re

285 Resolution of macular edema was more common in patients with DRSS impr

286 Diabetic macular edema was not associated with depressive symptom

287 .001]), whereas an increased risk of cystoid macular edema was not identified for those who received

288 % CI, 3.0%-6.4%), and clinically significant macular edema was observed among 2.0% (95% CI, 1.1%-3.3%

289 Macular edema was observed among 4.5% of people with dia

290 Macular edema was observed in 224 eyes (40.7%) and was a

291 Macular edema was present in 60% of eyes and was bilater

292 which is increased in patients with diabetic macular edema, was capable of cleaving netrin-1 into the

293 sed by multiadjusted odds of retinal cystoid macular edema, was not increased for patients receiving

294 ompared with ACIOL, complications of cystoid macular edema were higher in 10-0 polypropylene iris-sut

295 raphs of 30 eyes (20 patients) with diabetic macular edema were obtained.

296 nicity aged 18 years and older with diabetic macular edema who received intravitreal injections of be

297 20/40(+2), except in 1 patient with cystoid macular edema whose vision was 20/60(-) and 20/70(+1).

298 plexus were analyzed in relation to cystoid macular edema with retention of depth information.

299 atment was associated with a reduced risk of macular edema with visual acuity of 20/40 or worse.

300 he main outcome measure was the diagnosis of macular edema within 90 days of cataract surgery.